Counting of lymphocyte subpopulations using standard versus low-dose antiCD3 monoclonal antibody treatment.
The monoclonal anti-CD3 antibody is used as part of prophylaxis and also in treatment of rejection. In the present article we analyzed changes in different lymphocyte subpopulations after anti-CD3 treatment. T lymphocytes were decreased under anti-CD3 antibody administration, with a simultaneous increase in B lymphocytes but no changes in natural killer (NK)cells. No differences were found between patients administered anti-CD3 antibody (Ab) at 5 versus 2.5 mg/d. It is uncertain whether these changes may be implicated in the lack of response or in the prophylactic effects of anti-CD3 Ab.
González-Martínez
F
F
Instituto de Nefrologia y Urologia, and Centro de Nefrologia, Facultad de Medicina, Montevideo, Uruguay. frgonzalez@redfacil.com.uy
Curi
L
L
Núñez
H
H
González
A C
AC
Orihuela
N
N
González
G
G
Orihuela
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D017252:CD3 Complex